$243.00
-4-1.62%
At Close: -
$243.00
00.00%
After Hours: 4:35 PM EDT
15 minutes delayed
Alnylam Pharmaceuticals
ALNYNASDAQ
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Analyst Ratings, Price Targets, Predictions
Alnylam Pharmaceuticals Inc has a consensus price target of $226.96, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from UBS, RBC Capital, and Stifel on June 28, 2024, June 27, 2024, and June 27, 2024. With an average price target of $282.67 between UBS, RBC Capital, and Stifel, there's an implied 16.32% upside for Alnylam Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
RBC Capital
Stifel
Citigroup
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 18.52% | UBS | Eliana Merle | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 9.05% | RBC Capital | Luca Issi | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 21.4% | Stifel | Paul Matteis | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 19.75% | Citigroup | David Lebovitz | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 21.4% | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -34.57% | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | 16.05% | TD Cowen | Ritu Baral | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 7% | Evercore ISI Group | Liisa Bayko | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | 19.75% | Barclays | Gena Wang | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | 2.88% | RBC Capital | Luca Issi | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -14.81% | Wells Fargo | Tiago Fauth | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | 2.88% | Morgan Stanley | Michael Ulz | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 13.17% | Needham | Joseph Stringer | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 64.61% | HC Wainwright & Co. | Patrick Trucchio | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | -3.7% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 16.46% | Canaccord Genuity | Whitney Ijem | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 64.61% | HC Wainwright & Co. | Patrick Trucchio | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -7.41% | Chardan Capital | Keay Nakae | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -17.7% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | -3.7% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 62.55% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -38.27% | Cantor Fitzgerald | Olivia Brayer | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | -3.29% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/20/2024 | Buy Now | -3.29% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -33.74% | Wells Fargo | Tiago Fauth | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | -6.58% | Citigroup | David Lebovitz | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -3.29% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -7.41% | Chardan Capital | Keay Nakae | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -28.81% | Goldman Sachs | Salveen Richter | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
| 02/15/2024 | Buy Now | -17.7% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 02/14/2024 | Buy Now | -3.29% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/13/2024 | Buy Now | -27.57% | Morgan Stanley | Michael Ulz | $184 → $176 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/01/2024 | Buy Now | -30.04% | JP Morgan | Jessica Fung | $150 → $170 | Maintains | Neutral | Get Alert |
| 01/22/2024 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/18/2024 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/15/2023 | Buy Now | 62.55% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | -32.1% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/14/2023 | Buy Now | -10.7% | Piper Sandler | Edward Tenthoff | $210 → $217 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | -29.63% | Wells Fargo | Tiago Fauth | → $171 | Initiates | → Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | 62.55% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -5.35% | RBC Capital | Luca Issi | $235 → $230 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -24.69% | Morgan Stanley | Michael Ulz | $175 → $183 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | -30.04% | Cantor Fitzgerald | Olivia Brayer | $190 → $170 | Maintains | Neutral | Get Alert |
| 10/11/2023 | Buy Now | — | Oppenheimer | Leland Gershell | — | Downgrade | Outperform → Perform | Get Alert |
| 10/11/2023 | Buy Now | -3.29% | RBC Capital | Luca Issi | $270 → $235 | Maintains | Outperform | Get Alert |
| 10/11/2023 | Buy Now | 62.55% | HC Wainwright & Co. | Patrick Trucchio | $405 → $395 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | -27.98% | Morgan Stanley | Michael Ulz | $210 → $175 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | -3.7% | BMO Capital | Kostas Biliouris | $250 → $234 | Maintains | Outperform | Get Alert |
| 10/10/2023 | Buy Now | -4.12% | Citigroup | David Lebovitz | $266 → $233 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | -17.7% | Needham | Joseph Stringer | $240 → $200 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | -14.4% | Raymond James | Gary Nachman | → $208 | Initiates | → Outperform | Get Alert |
| 09/18/2023 | Buy Now | 66.67% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | -1.23% | Stifel | Paul Matteis | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | -21.81% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 09/14/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2023 | Buy Now | -21.81% | Cantor Fitzgerald | Olivia Brayer | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 08/08/2023 | Buy Now | 2.88% | Chardan Capital | Keay Nakae | → $250 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 66.67% | HC Wainwright & Co. | Patrick Trucchio | → $405 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | -13.58% | Morgan Stanley | Michael Ulz | $210 → $210 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | → $270 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 9.47% | Citigroup | David Lebovitz | $265 → $266 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 11.11% | RBC Capital | Luca Issi | $275 → $270 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 66.67% | HC Wainwright & Co. | Patrick Trucchio | $415 → $405 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | -17.7% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 07/12/2023 | Buy Now | -17.7% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/23/2023 | Buy Now | -17.7% | Cantor Fitzgerald | Olivia Brayer | $200 → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/22/2023 | Buy Now | -17.7% | Cantor Fitzgerald | Olivia Brayer | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 05/31/2023 | Buy Now | 13.17% | RBC Capital | Luca Issi | → $275 | Reiterates | Outperform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | 2.88% | BMO Capital | Kostas Biliouris | $200 → $250 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/05/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 70.78% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Reiterates | → Buy | Get Alert |
| 04/26/2023 | Buy Now | -9.47% | SMBC Nikko | David Hoang | → $220 | Initiates | → Neutral | Get Alert |
| 04/04/2023 | Buy Now | -13.58% | Morgan Stanley | Michael Ulz | $205 → $210 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | — | Bernstein | William Pickering | → $243 | Initiates | → Outperform | Get Alert |
| 03/03/2023 | Buy Now | -19.34% | JP Morgan | Jessica Fung | $200 → $196 | Maintains | Neutral | Get Alert |
| 03/03/2023 | Buy Now | 70.78% | HC Wainwright & Co. | Patrick Trucchio | → $415 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 19.75% | Canaccord Genuity | Whitney Ijem | $310 → $291 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | -15.64% | Morgan Stanley | Michael Ulz | $210 → $205 | Maintains | Equal-Weight | Get Alert |
| 02/24/2023 | Buy Now | 9.05% | Citigroup | David Lebovitz | $270 → $265 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 2.47% | Oppenheimer | Leland Gershell | $256 → $249 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 2.88% | Chardan Capital | Keay Nakae | → $250 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 25.1% | EF Hutton | Michael King | → $304 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | -1.23% | Needham | Joseph Stringer | → $240 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 25.1% | EF Hutton | Michael King | → $304 | Initiates | → Buy | Get Alert |
| 01/23/2023 | Buy Now | -41.15% | SVB Leerink | Mani Foroohar | $144 → $143 | Maintains | Market Perform | Get Alert |
| 01/18/2023 | Buy Now | 27.57% | Canaccord Genuity | Whitney Ijem | → $310 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | 4.12% | Piper Sandler | Edward Tenthoff | $226 → $253 | Maintains | Overweight | Get Alert |
| 11/07/2022 | Buy Now | -40.33% | SVB Leerink | Mani Foroohar | $142 → $145 | Maintains | Market Perform | Get Alert |
| 11/02/2022 | Buy Now | 70.78% | HC Wainwright & Co. | Patrick Trucchio | $430 → $415 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY) stock?
The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by UBS on June 28, 2024. The analyst firm set a price target for $288.00 expecting ALNY to rise to within 12 months (a possible 18.52% upside). 75 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by UBS, and Alnylam Pharmaceuticals maintained their buy rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on May 5, 2023 when BMO Capital raised their price target to $250. BMO Capital previously had a market perform for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on February 16, 2024 when Goldman Sachs changed their price target from $230 to $173 for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $253.00 to $288.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $243.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.